CK001

CK001 is a preclinical-stage chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by Guangdong Celconta Biotechnology. The therapy is built upon the company's proprietary CAR-NK technology platform, which aims to engineer natural killer cells to enhance their innate ability to recognize and eliminate specific target cells. While the specific antigen target and primary disease indications for CK001 have not been publicly disclosed by the developer, the program represents a key asset in their pipeline of next-generation cell therapies, typically intended for the treatment of hematologic malignancies or solid tumors. The therapy is currently undergoing preclinical research to evaluate its safety and efficacy profile.